Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

1. New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights.The journal of liquid biopsy · 2024
   Review
2. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.Frontiers in immunology · 2019
   Review
3. Current status of stereotactic ablative body radiotherapy in the UK: six years of progress.BJR open · 2019
   Article
4. Palliative radiotherapy.BMJ (Clinical research ed.) · 2018
   Review
5. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.Lung cancer (Amsterdam, Netherlands) · 2017
   Article

Corrections and comments

• Comment on
  Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.2018

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.